EMcision was founded by internationally renowned surgeon and inventor of medical devices, Professor Nagy Habib, to develop proprietary medical devices based on proven RF technology for the surgical community. Devices for endoscopists and interventional radiologists soon followed. In 2002, EMcision developed the Habib™ 4X for the treatment of liver cancer, which has the reputation of being the #1 hepatic resection device in the U.S.
The company combines scientific, commercial and management skills, brought together in a working partnership to develop and commercialize medical devices that are clinically relevant, cost-effective and enhance the quality of life of cancer patients. EMcision's R&D, engineering and commercialization operations are based in Montreal, and clinical activities are based at the Imperial College London (U.K.) and Hammersmith Hospital.
To enhance cancer patients’ quality of life by applying empathy to precision.
To advance surgical and medical techniques by harnessing the power and accuracy of radiofrequency energy for specific applications in percutaneous procedures and open, laparoscopic, vascular and endoscopic surgeries.
To deliver innovation without boundaries by bridging academic, R&D, engineering and commercial areas of expertise with real-world clinical experience, and by developing distribution opportunities that make EMcision products available worldwide.
Prof. Nagy Habib
Chairman and Medical Director
Chief Executive Officer
General Manager - UK
General Manager - Canada